» Articles » PMID: 28893733

Topological Analysis Reveals a PD-L1-associated Microenvironmental Niche for Reed-Sternberg Cells in Hodgkin Lymphoma

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2017 Sep 13
PMID 28893733
Citations 175
Authors
Affiliations
Soon will be listed here.
Abstract

Signaling between programmed cell death protein 1 (PD-1) and the PD-1 ligands (PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg (HRS) cells to evade antitumor immunity in classical Hodgkin lymphoma (cHL). Copy number alterations of 9p24.1/()() contribute to robust PD-L1 and PD-L2 expression by HRS cells. PD-L1 is also expressed by nonmalignant tumor-associated macrophages (TAMs), but the relationships among PD-L1 HRS cells, PD-L1 TAMs, and PD-1 T cells remain undefined. We used multiplex immunofluorescence and digital image analysis to examine the topography of PD-L1 and PD-1 cells in the tumor microenvironment (TME) of cHL. We find that the majority of PD-L1 in the TME is expressed by the abundant PD-L1 TAMs, which physically colocalize with PD-L1 HRS cells in a microenvironmental niche. PD-L1 TAMs are enriched for contacts with T cells, and PD-L1 HRS cells are enriched for contacts with CD4 T cells, a subset of which are PD-1 Our data define a unique topology of cHL in which PD-L1 TAMs surround HRS cells and implicate CD4 T cells as a target of PD-1 blockade.

Citing Articles

Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors.

Shanmugam V, Tokcan N, Chafamo D, Sullivan S, Borji M, Martin H bioRxiv. 2025; .

PMID: 39896575 PMC: 11785141. DOI: 10.1101/2025.01.24.631210.


Topological importance of CD8 T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma.

Takahashi H, Ito S, Nakanishi Y, Miura K, Nishimaki H, Nakagawa M Ann Hematol. 2025; .

PMID: 39820429 DOI: 10.1007/s00277-025-06189-1.


Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.

Paczkowska J, Tang M, Wright K, Song L, Luu K, Shanmugam V Nat Commun. 2024; 15(1):10740.

PMID: 39737927 PMC: 11686379. DOI: 10.1038/s41467-024-54512-7.


The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma.

Cashen A Front Oncol. 2024; 14:1392653.

PMID: 39502311 PMC: 11534676. DOI: 10.3389/fonc.2024.1392653.


Hodgkin/Reed-Sternberg cells induce GPNMB expression and release from macrophages to suppress T-cell responses to the Epstein-Barr virus-encoded LMP2A protein.

Masand N, Perry T, Pugh M, Fennell E, Hennessy A, Wei W Haematologica. 2024; 110(1):193-199.

PMID: 39219456 PMC: 11694118. DOI: 10.3324/haematol.2024.285319.


References
1.
Skinnider B, Mak T . The role of cytokines in classical Hodgkin lymphoma. Blood. 2002; 99(12):4283-97. DOI: 10.1182/blood-2002-01-0099. View

2.
Farrar M, Schreiber R . The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993; 11:571-611. DOI: 10.1146/annurev.iy.11.040193.003035. View

3.
Roemer M, Advani R, Redd R, Pinkus G, Natkunam Y, Ligon A . Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res. 2016; 4(11):910-916. PMC: 5210180. DOI: 10.1158/2326-6066.CIR-16-0201. View

4.
Green M, Monti S, Rodig S, Juszczynski P, Currie T, ODonnell E . Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-77. PMC: 2995356. DOI: 10.1182/blood-2010-05-282780. View

5.
Haabeth O, Tveita A, Fauskanger M, Schjesvold F, Lorvik K, Hofgaard P . How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?. Front Immunol. 2014; 5:174. PMC: 3995058. DOI: 10.3389/fimmu.2014.00174. View